A clinical trial involving abaloparatide began recruiting as of June 1, 2026. The study, registered as NCT07616401, is titled "MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis."
The trial's current status is listed as recruiting. No phase designation applies to this study, as its phase is listed as not applicable. The trial examines abaloparatide alongside romosozumab in the context of postmenopausal osteoporosis, with a focus on microRNA and other markers related to therapeutic response.
No results have been posted for this trial at this time. The event data does not include information on trial design, enrollment targets, or expected completion dates beyond what is stated here.
Abaloparatide is an approved compound. This update reflects only the recruitment status and title of the registered trial as of the date provided. Readers interested in additional context can consult the compound overview for more background on abaloparatide.